Literature DB >> 24681738

Risk factors for recurrence and prognosis of low-grade endometrial adenocarcinoma; vaginal versus other sites.

Elizabeth J Moschiano1, Denise A Barbuto, Christine Walsh, Kanwaljit Singh, Elizabeth D Euscher, Andres A Roma, Rouba Ali-Fehmi, Elizabeth E Frauenhoffer, Delia P Montiel, Insun Kim, Bojana Djordjevic, Anais Malpica, Sung Ran Hong, Elvio G Silva.   

Abstract

Endometrial adenocarcinoma is the most common gynecologic cancer in the United States. The prognosis is generally favorable, however, a significant number of patients do develop local or distant recurrence. The most common site of recurrence is vaginal. Our aim was to better characterize patients with vaginal recurrence of low-grade endometrioid adenocarcinoma with respect to associated tumor parameters and clinical outcome. We compiled 255 cases of low-grade (FIGO Grade I or II) endometrioid adenocarcinoma on hysterectomy specimens with lymph node dissection. A total of 113 cases with positive lymph nodes or recurrent disease were included in our study group. Seventy-three cases (13 Grade 1, 60 Grade 2) developed extravaginal recurrence and 40 cases (7 Grade 1, 33 Grade 2) developed vaginal recurrence. We evaluated numerous tumor parameters including: percentage myoinvasion, presence of microcystic, elongated, and fragmented pattern of myoinvasion, lymphovascular space invasion, and cervical involvement. Clinical follow-up showed that 30% (34/113) of all patients with recurrent disease died as a result of their disease during our follow-up period, including 31 (42.5%) with extravaginal recurrence and 3 (7.5%) with primary vaginal recurrence (P=0.001). The 3 patients with vaginal recurrence developed subsequent extravaginal recurrence before death. Vaginal recurrence patients show increased cervical involvement by tumor, but lack other risk factors associated with recurrent disease at other sites. There were no deaths among patients with isolated vaginal recurrence, suggesting that vaginal recurrence is not a marker of aggressive tumor biology.

Entities:  

Mesh:

Year:  2014        PMID: 24681738     DOI: 10.1097/PGP.0b013e31829c6757

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  4 in total

1.  Feasibility of a reduced field-of-view diffusion-weighted (rFOV) sequence in assessment of myometrial invasion in patients with clinical FIGO stage I endometrial cancer.

Authors:  Priya Bhosale; Jingfei Ma; Revathy Iyer; Preetha Ramalingam; Wei Wei; Pamela Soliman; Michael Frumovitz; Vikas Kundra
Journal:  J Magn Reson Imaging       Date:  2015-07-16       Impact factor: 4.813

2.  The Microcystic, Elongated, and Fragmented (MELF) Pattern of Invasion: A Single Institution Report of 464 Consecutive FIGO Grade 1 Endometrial Endometrioid Adenocarcinomas.

Authors:  Amy S Joehlin-Price; Kelsey E McHugh; Julie A Stephens; Zaibo Li; Floor J Backes; David E Cohn; David W Cohen; Adrian A Suarez
Journal:  Am J Surg Pathol       Date:  2017-01       Impact factor: 6.394

3.  MR- versus CT-based high-dose-rate interstitial brachytherapy for vaginal recurrence of endometrial cancer.

Authors:  Sophia C Kamran; Matthias M Manuel; Paul Catalano; Linda Cho; Antonio L Damato; Larissa J Lee; Ehud J Schmidt; Akila N Viswanathan
Journal:  Brachytherapy       Date:  2017-08-17       Impact factor: 2.362

4.  Predicting poor prognosis recurrence in women with endometrial cancer: a nomogram developed by the FRANCOGYN study group.

Authors:  Lobna Ouldamer; Sofiane Bendifallah; Gilles Body; Cyril Touboul; Olivier Graesslin; Emilie Raimond; Pierre Collinet; Charles Coutant; Vincent Lavoué; Jean Lévêque; Emile Daraï; Marcos Ballester
Journal:  Br J Cancer       Date:  2016-11-08       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.